Built In Publish Date: September 9, 2022 Read the Full Article >> About the company: Founded in 2015, OM1 developed its data cloud to provide advanced technological tools for researchers and support their quest to find new ways of understanding and treating chronic conditions. Yaning Zhang, Sr. Software Engineer, shared how OM1 turns data into insight:[…]
BioPharma Dive Published Online: July 18, 2022 Read the Full Article>> Identifying patients ‘outside the clinic’ can provide significant benefits for researchers and population health managers. Better understanding of patient cohorts can shed light on patient journeys, help optimize decisions around treatment choice and timing and inform the development of new therapies and intervention programs.[…]
Read the Press Release >> BOSTON, June 23, 2022 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the publication of their validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis in the Multiple Sclerosis Journal by[…]
First Published June 22, 2022 – Multiple Sclerosis Journal Assessment of multiple sclerosis (MS) disease activity is critical for understanding treatment effectiveness, informing treatment decisions, and monitoring disease progression. Magnetic resonance imaging (MRI) findings, clinician-administered assessments, and patient questionnaires are used to measure disease activity and track changes over time. The Expanded Disability Status Scale[…]
BMJ Journals Published: May 20, 2021 Read the Full Manuscript >> Objective Use of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in routine clinical practice is inconsistent, and availability of clinician-recorded SLEDAI scores in real-world datasets is limited. This study aimed to validate a machine learning model to estimate SLEDAI score categories using clinical notes[…]
